MCL1 and non-Hodgkin lymphoma: Since some BCL2High NHL cell lines are relatively resistant to navitoclax (EC50 >2 μM; Figure 1a and Supplementary Table 1), we treated BCL2High NHL cell lines (SU-DHL-4, WSU-NHL and WSU-DLCL2) with navitoclax or venetoclax and evaluated interactions of BIM with BCL-2 and MCL-1.